by Kathy Giusti and Richard G. Hamermesh 

Recent years have seen record numbers of drug approvals. In 2019 alone, there were incredible strides in developing treatments for notoriously-hard-to-treat diseases, including metastatic breast cancer, sickle cell disease, and bladder cancer. But despite these accomplishments, much more progress needs to be made. How can we accelerate the pace of the quest to find cures?

*Read the full article on Harvard Business Review*